{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"129","value":"252"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"59"}],"units":"Participants"}],"title":"Day 1"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"74.2","value":"266"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"48"}],"units":"Participants"}],"title":"Day 43"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"57.7","value":"274"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"30"}],"units":"Participants"}],"title":"Day 85"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"65.0","value":"315"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"23"}],"units":"Participants"}],"title":"Day 169"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"70.1","value":"318"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"15"}],"units":"Participants"}],"title":"Day 253"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"48.3","value":"373"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"6"}],"units":"Participants"}],"title":"Day 337"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"71.5","value":"453"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"4"}],"units":"Participants"}],"title":"Day 421"}],"denoms":[{"counts":[{"groupId":"OG000","value":"88"}],"units":"Participants"}],"description":"Serum concentration at end of infusion (CEOI) of Avelumab is reported.","dispersionType":"Standard Deviation","groups":[{"description":"Participants with metastatic Merkel cell carcinoma (MCC) after failing first-line chemotherapy received Avelumab at a dose of 10 milligram per kilogram (mg/kg) as 1-hour intravenous infusion once every 2 weeks until therapeutic failure, significant clinical deterioration, unacceptable toxicity, or any criterion for withdrawal from the trial or investigational medicinal product occurs.","id":"OG000","title":"Part A: Avelumab"}],"paramType":"MEAN","populationDescription":"Pharmacokinetic analysis set consists of all participants who received at least 1 dose of avelumab, and provide at least 1 measurable post-dose concentration. Here \"Number analyzed\" signifies those participants who were evaluable at specified timepoints","reportingStatus":"POSTED","timeFrame":"Day 1, 43, 85, 169, 253, 337 and 421","title":"Part A: Serum Concentration at End of Infusion (CEOI) of Avelumab","type":"SECONDARY","unitOfMeasure":"Micrograms per milliliter"}